Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2025-12-24 @ 7:09 PM
NCT ID:
NCT03022903
Eligibility Criteria:
Inclusion Criteria:
* Patients older than 19 and younger than 70 years
* Give written informed consent prior to any study procedures being conducted, and candidates will authorize the release and use of protected health information (PHI)
* Diagnosed with distal lateral subungual onychomycosis (DLSO) of the great toe with both positive potassium hydroxide (KOH) and positive culture growth of Trichophyton rubrum
* No topical treatment for DLSO in the preceding 2 weeks and no oral treatment for DLSO (itraconazole or terbinafine) in the preceding 8 weeks
* At lease 20% of target great toe nail affected
Exclusion Criteria:
* Unable to comply with the protocol (as defined y the investigator; i.e. drug or alcohol abuse or history of noncompliance)
* Patients with active nail disease that would confound evaluation of DLSO, such as psoriasis
* Patients with greater than 6 toenails affected
* Over 90% of target great toe affected
* Evidence of fingernail fungal infection
* Patients with recurrent serious infections or have been hospitalized in the preceding 6 months for infection
* Patients with known history of HIV or hepatitis B or C infection
* Patients with severe, progressive, or uncontrolled with renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurologic disease
* Any subject who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
19 Years
Maximum Age:
70 Years
Study:
NCT03022903
Study Brief:
Protocol Section:
NCT03022903